N-toluoyl piperidine: effective repellent against Aedes aegypti(L) mosquitoes; RN given refers to cpd with unspecified methyl-locant on benzoyl group; see also record for R-228, the meta-methyl cpd
ID Source | ID |
---|---|
PubMed CID | 83672 |
SCHEMBL ID | 257545 |
MeSH ID | M0085558 |
Synonym |
---|
HMS1478B17 |
nsc-38133 |
nsc38133 |
13707-23-8 |
n-toluoyl piperidine |
IDI1_020765 |
CHEMDIV3_001799 |
1-(4-methylbenzoyl)piperidine |
AQ-390/09693049 |
BRD-K07582751-001-01-4 |
28134-21-6 |
AKOS001630686 |
piperidine, 1-(4-methylbenzoyl)- |
(4-methylphenyl)-piperidin-1-ylmethanone |
ai3-31640 |
nsc 38133 |
methanone,(4-methylphenyl)-1-piperidinyl- |
piperidin-1-yl(p-tolyl)methanone |
SCHEMBL257545 |
sr-01000454295 |
SR-01000454295-1 |
DTXSID60877250 |
1-piperidinyl(p-tolyl)methanone |
methanone, (4-methylphenyl)-1-piperidinyl- |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |